Pertussis resurgence: Perspectives from the working group meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge

Journal of Infectious Diseases

Volumn 209, Issue SUPPL. 1, 2014, Pages

  Burns, Drusilla L ^a   Meade, Bruce D ^b   Messionnier, Nancy E ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Meade Biologics   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

pertussis; pertussis vaccines; vaccine effectiveness

Indexed keywords

PERTUSSIS; PERTUSSIS VACCINES; VACCINE EFFECTIVENESS;

BIOMEDICAL RESEARCH; COMMUNICABLE DISEASES, EMERGING; DRUG DISCOVERY; HUMANS; PERTUSSIS VACCINE; VACCINATION; WHOOPING COUGH;

EID: 84899003026     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit491     Document Type: Article

References (25)

1. Clark TA, Messionnier NE, Hadler SC. Pertussis control: Time for something new?. Trends Microbiol 2012; 20:211-3
2. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (.Tdap) in pregnant women - Advisory Committee on Immunization Practices (.ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131-5
3. Spokes PJ, Quinn HE, McAnulty JM. Review of the 2008-2009 pertussis epidemic in NSW: Notifications and hospitalizations. NSW Public Health Bull 2010; 21:167-73
4. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32
5. Tartof SY, Lewis M, Kenyon C, et al.Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52
6. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56:1248-54
7. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children N. Engl J Med 2012; 367:1012-9
8. Ryan M, Murphy G, Ryan E, et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998; 93:1-10. (Pubitemid 28133089)
9. Higgs R, Higgins SC, Ross PJ, Mills KHG. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012; 5:485-500
10. Ausiello CM, Urbani F, LaSala A, Lande R, Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acelllular pertussis vaccines. Infect Immun 1997; 65:2168-74. (Pubitemid 27237293)
11. RyanM,Murphy G, Gothefors L, Nilsson L, Storsaeter J,Mills KHG. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997; 175:1246-50. (Pubitemid 27176522)
12. Ross PJ, Sutton CE, Higgins S, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: Towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013; 9:e1003264
13. Advani A, Gustafsson L, Ahren C, Mooi FR, Hallander HO. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine 2011; 29: 3438-42
14. Mooi FR. Bordetella pertussis and vaccination: The persistence of a genetically monomorphic pathogen. Infect Genet Evol 2010; 10:36-49
15. Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella L, Tatti KM. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis 2012; 18:1248-55
16. Barkoff A-M, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vacc Immunol 2012; 19:1703-4
17. Otsuka N, Han H-J, Toyoizumi-Ajisaka H, et al. Prevalence and genetic characterization of pertatin-deficient Bordetella pertussis in Japan. PLoS One 2012; 7:e31985
18. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009; 27:6034-41
19. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013; 368:583-4
20. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Ped Infect Dis J 2005; 24:S62-5
21. Wood N, Siegrist C-A. Neonatal immunization: Where do we stand?. Curr Opin Infect Dis 2011; 24:190-5
22. Knuf M, Schmitt H-J,Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655-60
23. Wood N, McIntyre P, Marshall H, Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010; 29:209-15
24. Halasa NB, O'Shea A, Shi JR, LaFleur BJ, Edwards KM. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008; 153:327-32
25. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. Nonhuman primate model of pertussis. Infect Immun 2012; 80:1530-6